ACRS - Company ID 0001557746
The table below shows Aclaris Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$18.15M | -$13.06M | -$20.82M | -$26.35M | -$20.97M | -$12.23M |
| Capital expenditure | $13.00K | $43.00K | $135.00K | $553.00K | $164.00K | - |
| Investing cash flow | -$30.93M | $19.12M | $16.83M | $25.80M | $29.93M | -$75.31M |
| Dividends paid | - | - | - | - |
Aclaris Therapeutics, Inc. reported operating cash flow of -$47.11M for fiscal year 2025. That is down 134.7% from -$20.07M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$34.60M (FY 2016) to -$47.11M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $57.78M | -$275.00K | -$55.00K | - | $30.00K | $100.75M |